Jazz Pharmaceuticals (JAZZ) PT Raised to $235 at Barclays
Get Alerts JAZZ Hot Sheet
Price: $107.43 -0.82%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Barclays analyst Balaji Prasad raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $235.00 (from $233.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
- Adyen NV (ADYEN:NA) (ADYYF) PT Lowered to EUR1,810 at Morgan Stanley
- Andritz AG (ANDR:AV) (ADRZY) PT Lowered to EUR78 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!